OriGene Technologies, Inc., a Rockville, MD-based life sciences company dedicated to support academic institutions, and pharmaceutical and biotech companies in their research of gene functions and drug discovery, completed a $16m Series B financing
The round was led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO with participation from previous investors Morningside Venture Investments and President International Development Corp. (PIDC).
The proceeds from the funding will enable the OriGene to continue to build OriGene’s TrueMAB™ monoclonal antibody collection covering the entire human genome of approximately 20,000 genes.
FinSMEs
17/03/2010